ArticlePLOS global public health2024
Factors associated with viral load re-suppression after enhanced adherence counseling among people living with HIV with an initial high viral load result in selected Nigerian states.
Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Poor adherence to second-line antiretroviral therapy and its contributing factors among people living with HIV in Addis Ababa, Ethiopia.AIDS research and therapy · 2026Article
- Article
- Community-based enhanced adherence counseling among people living with HIV in Ethiopia: outcomes and key predictors of viral suppression.AIDS research and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The WHO recommends monitoring viral load (VL) to gauge ART efficacy among People Living with HIV (PLHIV). Low suppression rates persist in low- and middle-income countries due to poor adherence. Enhanced Adherence Counseling (EAC) aims to improve adherence and treatment outcomes. This study, part of the Reaching Impact Saturation and Epidemic Control (RISE) project in Nigeria, analyzes factors affecting viral re-suppression post-EAC. It aims to inform clinical decisions and improve PLHIV health outcomes in the country. This was a retrospective analysis of a de-identified client-level dataset of unsuppressed VL clients who were current on treatment at the end of June 2022 and subsequently enrolled in the EAC program. A log-binomial regression model was used to report crude and adjusted risk ratio with 95% Confidence Intervals (95% CI) and a p-value of 0.05 to determine the association between clinical characteristics and suppression of VL post-EAC in the RISE program (July 2021 to June 2022). A total of 1607 clients with initial high VL who completed EAC were included in this analysis out of which 1454 (91%) were virally suppressed. The median time to completion of EAC was 8 weeks and the median time for post EAC VL test was 8 weeks. Following EAC, PLHIV in the 10-19 years age band were 10% more likely to be re-suppressed (ARR: 1.10; 95% CI 1.01 to 1.19). In addition, there was a 50% reduced likelihood of viral re-suppression among PLHIV on second-line regimens compared to PLHIV on first-line regimens (ARR: 0.50; 95% CI 0.41 to 0.62). Findings show that Age and ART regimen were significant predictors of VLS. More targeted outreach of EAC amongst second-line regimens and ages 10 and above is necessary to ensure better VLS within these groups.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.